Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 34

1.

Clinical Monitoring in a Federally Funded Environment: Evolution and Opportunities in the Cardiovascular Cell Therapy Research Network.

Mathew SR, Lucas KD, Sayre SL, Bettencourt J, Collins T, Leach D, Olson RE, Taylor DA, Moyé L.

Monitor (Assoc Clin Pharmacol). 2014 Feb;28(1):31-36. No abstract available.

2.

Rationale and design for PACE: patients with intermittent claudication injected with ALDH bright cells.

Perin EC, Murphy M, Cooke JP, Moyé L, Henry TD, Bettencourt J, Gahremanpour A, Leeper N, Anderson RD, Hiatt WR, Lima JA, Venkatesh B, Sayre SL, Vojvodic RW, Taylor DA, Ebert RF, Hirsch AT; Cardiovascular Cell Therapy Research Network.

Am Heart J. 2014 Nov;168(5):667-73. doi: 10.1016/j.ahj.2014.07.021. Epub 2014 Jul 30.

PMID:
25440794
3.

Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial.

Schutt RC, Trachtenberg BH, Cooke JP, Traverse JH, Henry TD, Pepine CJ, Willerson JT, Perin EC, Ellis SG, Zhao DX, Bhatnagar A, Johnstone BH, Lai D, Resende M, Ebert RF, Wu JC, Sayre SL, Orozco A, Zierold C, Simari RD, Moyé L, Cogle CR, Taylor DA; Cardiovascular Cell Therapy Research Network (CCTRN).

Circ Res. 2015 Jan 2;116(1):99-107. doi: 10.1161/CIRCRESAHA.116.304710. Epub 2014 Nov 18.

PMID:
25406300
4.

Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes.

Cogle CR, Wise E, Meacham AM, Zierold C, Traverse JH, Henry TD, Perin EC, Willerson JT, Ellis SG, Carlson M, Zhao DX, Bolli R, Cooke JP, Anwaruddin S, Bhatnagar A, da Graca Cabreira-Hansen M, Grant MB, Lai D, Moyé L, Ebert RF, Olson RE, Sayre SL, Schulman IH, Bosse RC, Scott EW, Simari RD, Pepine CJ, Taylor DA; Cardiovascular Cell Therapy Research Network (CCTRN).

Circ Res. 2014 Oct 24;115(10):867-74. doi: 10.1161/CIRCRESAHA.115.304353. Epub 2014 Aug 18.

PMID:
25136078
5.

Bone marrow mononuclear cell therapy for acute myocardial infarction: a perspective from the cardiovascular cell therapy research network.

Simari RD, Pepine CJ, Traverse JH, Henry TD, Bolli R, Spoon DB, Yeh E, Hare JM, Schulman IH, Anderson RD, Lambert C, Sayre SL, Taylor DA, Ebert RF, Moyé LA.

Circ Res. 2014 May 9;114(10):1564-8. doi: 10.1161/CIRCRESAHA.114.303720. Review.

6.

Implementation of cardovascular cell therapy network trials: challenges, innovation and lessons learned from experience in the CCTRN.

Park KE, Moyé LA, Henry TD, Perin EC, Sayre SL, Bettencourt J, Vojvodic RW, Olson RE, Pepine CJ; CCTRN.

Expert Rev Cardiovasc Ther. 2013 Nov;11(11):1495-502. doi: 10.1586/14779072.2013.839943. Epub 2013 Oct 23.

7.

Anatomy of an evidence-based policy.

Blankenship S, Lucas A, Sayre S.

Nursing. 2013 Jun;43(6):1-5. doi: 10.1097/01.NURSE.0000429799.26483.64. No abstract available.

PMID:
23685681
8.

Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial.

Traverse JH, Henry TD, Pepine CJ, Willerson JT, Zhao DX, Ellis SG, Forder JR, Anderson RD, Hatzopoulos AK, Penn MS, Perin EC, Chambers J, Baran KW, Raveendran G, Lambert C, Lerman A, Simon DI, Vaughan DE, Lai D, Gee AP, Taylor DA, Cogle CR, Thomas JD, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Kappenman C, Westbrook L, Piller LB, Simpson LM, Baraniuk S, Loghin C, Aguilar D, Richman S, Zierold C, Spoon DB, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN).

JAMA. 2012 Dec 12;308(22):2380-9. Erratum in: JAMA. 2013 Jan 23;309(4):343.

9.

Impact of navigators on completion of steps in the kidney transplant process: a randomized, controlled trial.

Sullivan C, Leon JB, Sayre SS, Marbury M, Ivers M, Pencak JA, Bodziak KA, Hricik DE, Morrison EJ, Albert JM, Navaneethan SD, Reyes CM, Sehgal AR.

Clin J Am Soc Nephrol. 2012 Oct;7(10):1639-45. doi: 10.2215/CJN.11731111. Epub 2012 Jul 12.

10.

Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial.

Perin EC, Willerson JT, Pepine CJ, Henry TD, Ellis SG, Zhao DX, Silva GV, Lai D, Thomas JD, Kronenberg MW, Martin AD, Anderson RD, Traverse JH, Penn MS, Anwaruddin S, Hatzopoulos AK, Gee AP, Taylor DA, Cogle CR, Smith D, Westbrook L, Chen J, Handberg E, Olson RE, Geither C, Bowman S, Francescon J, Baraniuk S, Piller LB, Simpson LM, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN).

JAMA. 2012 Apr 25;307(16):1717-26. doi: 10.1001/jama.2012.418. Epub 2012 Mar 24.

11.

Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial.

Traverse JH, Henry TD, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Forder JR, Byrne BJ, Hatzopoulos AK, Penn MS, Perin EC, Baran KW, Chambers J, Lambert C, Raveendran G, Simon DI, Vaughan DE, Simpson LM, Gee AP, Taylor DA, Cogle CR, Thomas JD, Silva GV, Jorgenson BC, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Smith DX, Baraniuk S, Piller LB, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD; Cardiovascular Cell Therapy ResearchNetwork.

JAMA. 2011 Nov 16;306(19):2110-9. doi: 10.1001/jama.2011.1670. Epub 2011 Nov 14.

12.

Oversight and management of a cell therapy clinical trial network: experience and lessons learned.

Moyé LA, Sayre SL, Westbrook L, Jorgenson BC, Handberg E, Anwaruddin S, Wagner KA, Skarlatos SI.

Contemp Clin Trials. 2011 Sep;32(5):614-9. doi: 10.1016/j.cct.2011.05.003. Epub 2011 May 17.

13.

LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction.

Traverse JH, Henry TD, Vaughan DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Simpson LM, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Baraniuk S, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moyè LA, Simari RD; Cardiovascular Cell Therapy Research Network.

Tex Heart Inst J. 2010;37(4):412-20.

14.

Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and design.

Willerson JT, Perin EC, Ellis SG, Pepine CJ, Henry TD, Zhao DX, Lai D, Penn MS, Byrne BJ, Silva G, Gee A, Traverse JH, Hatzopoulos AK, Forder JR, Martin D, Kronenberg M, Taylor DA, Cogle CR, Baraniuk S, Westbrook L, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moyé LA, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN).

Am Heart J. 2010 Aug;160(2):215-23. doi: 10.1016/j.ahj.2010.03.029.

15.

Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction.

Traverse JH, Henry TD, Vaughan DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Piller LB, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moye' LA, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN).

Am Heart J. 2009 Sep;158(3):356-63. doi: 10.1016/j.ahj.2009.06.009. Epub 2009 Jul 23. Erratum in: Am Heart J. 2009 Dec;158(6):1045. Vaughn, Douglas E [corrected to Vaughan, Douglas E].

16.

Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial.

Sullivan C, Sayre SS, Leon JB, Machekano R, Love TE, Porter D, Marbury M, Sehgal AR.

JAMA. 2009 Feb 11;301(6):629-35. doi: 10.1001/jama.2009.96.

PMID:
19211470
17.

APOE/C1/C4/C2 hepatic control region polymorphism influences plasma apoE and LDL cholesterol levels.

Klos K, Shimmin L, Ballantyne C, Boerwinkle E, Clark A, Coresh J, Hanis C, Liu K, Sayre S, Hixson J.

Hum Mol Genet. 2008 Jul 1;17(13):2039-46. doi: 10.1093/hmg/ddn101. Epub 2008 Mar 31.

18.

Illusory predictors: Generalizability of findings in cocaine treatment retention research.

Stotts AL, Mooney ME, Sayre SL, Novy M, Schmitz JM, Grabowski J.

Addict Behav. 2007 Dec;32(12):2819-36. Epub 2007 May 3. Review.

19.

Adding MEMS feedback to behavioral smoking cessation therapy increases compliance with bupropion: a replication and extension study.

Mooney ME, Sayre SL, Hokanson PS, Stotts AL, Schmitz JM.

Addict Behav. 2007 Apr;32(4):875-80. Epub 2006 Jul 12.

PMID:
16839698
20.

Moderators of delay tolerance in treatment-seeking cocaine users.

Chawdhary A, Sayre SL, Green C, Schmitz JM, Grabowski J, Mooney ME.

Addict Behav. 2007 Feb;32(2):370-6. Epub 2006 May 18.

PMID:
16713126
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk